192 related articles for article (PubMed ID: 31728054)
1. Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children's Oncology Group Studies P9904 and P9905.
Winick N; Martin PL; Devidas M; Shuster J; Borowitz MJ; Paul Bowman W; Larsen E; Pullen J; Carroll A; Willman C; Hunger SP; Carroll WL; Camitta BM
Leukemia; 2020 Apr; 34(4):1006-1016. PubMed ID: 31728054
[TBL] [Abstract][Full Text] [Related]
2. Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906.
Bowman WP; Larsen EL; Devidas M; Linda SB; Blach L; Carroll AJ; Carroll WL; Pullen DJ; Shuster J; Willman CL; Winick N; Camitta BM; Hunger SP; Borowitz MJ
Pediatr Blood Cancer; 2011 Oct; 57(4):569-77. PubMed ID: 21360654
[TBL] [Abstract][Full Text] [Related]
3. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
[TBL] [Abstract][Full Text] [Related]
4. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
[TBL] [Abstract][Full Text] [Related]
5. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Wade R; Mitchell C; Hancock J; Hough R; Rowntree C; Richards S
Lancet Oncol; 2013 Mar; 14(3):199-209. PubMed ID: 23395119
[TBL] [Abstract][Full Text] [Related]
6. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy.
Aricò M; Valsecchi MG; Rizzari C; Barisone E; Biondi A; Casale F; Locatelli F; Lo Nigro L; Luciani M; Messina C; Micalizzi C; Parasole R; Pession A; Santoro N; Testi AM; Silvestri D; Basso G; Masera G; Conter V
J Clin Oncol; 2008 Jan; 26(2):283-9. PubMed ID: 18182669
[TBL] [Abstract][Full Text] [Related]
7. [Modified BFM-90 regimen greatly improves treatment outcomes of chinese childhood and adolescent lymphoblastic lymphoma].
Sun XF; Zhen ZJ; Liu DG; Xia ZJ; Huang HQ; Zhang L; Zhou ZM; Li YH; Xia Y; Ling JY; Guan ZZ
Zhonghua Zhong Liu Za Zhi; 2007 Jan; 29(1):58-61. PubMed ID: 17575697
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
Paganin M; Zecca M; Fabbri G; Polato K; Biondi A; Rizzari C; Locatelli F; Basso G
Leukemia; 2008 Dec; 22(12):2193-200. PubMed ID: 18754029
[TBL] [Abstract][Full Text] [Related]
9. Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
Möricke A; Lauten M; Beier R; Odenwald E; Stanulla M; Zimmermann M; Attarbaschi A; Niggli F; Schrappe M
Klin Padiatr; 2013 May; 225 Suppl 1():S50-6. PubMed ID: 23700057
[TBL] [Abstract][Full Text] [Related]
10. [Improved results in children with acute lymphoblastic leukemia treated with the ALL-BFM 90 protocol in the Czech Republic].
Starý J; Gajdos P; Blazek B; Ptoszková H; Mihál V; Pospísilová D; Hrstková H; Dembická D; Kopecná L; Slavík Z; Hak J; Procházková D; Zahálka F; Cerná Z; Jabali Y; Timr P; Vávra V; Mydlil J; Hrusák O; Trka J
Cas Lek Cesk; 2003; 142(7):404-9. PubMed ID: 14515443
[TBL] [Abstract][Full Text] [Related]
11. Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol.
Li XY; Li JQ; Luo XQ; Wu XD; Sun X; Xu HG; Li CG; Liu RY; Sun XF; Chen HQ; Lin YD; Li CK; Fang JP
BMC Cancer; 2021 Jan; 21(1):59. PubMed ID: 33435902
[TBL] [Abstract][Full Text] [Related]
12. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia.
Panzer-Grümayer ER; Schneider M; Panzer S; Fasching K; Gadner H
Blood; 2000 Feb; 95(3):790-4. PubMed ID: 10648387
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncology Group Study (E3486).
Wiernik PH; Cassileth PA; Leong T; Hoagland HC; Bennett JM; Paietta E; Oken MM;
Leuk Lymphoma; 2003 Sep; 44(9):1515-21. PubMed ID: 14565653
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of modified BFM-90 regimen on children and adolescents with T cell lymphoblastic lymphoma: a report of 20 cases].
Sun XF; Jiang WQ; Liu DG; Xia ZJ; Huang HQ; Zhang L; Li YH; Zhou ZM; Zhen ZJ; Xia Y; He YJ; Guan ZZ
Ai Zheng; 2004 Dec; 23(12):1687-91. PubMed ID: 15601561
[TBL] [Abstract][Full Text] [Related]
15. Improved outcome for acute lymphoblastic leukemia in children of a developing country: results of the Chilean National Trial PINDA 87.
Campbell M; Salgado C; Quintana J; Becker A; Vargas L; Cabrera ME; Beresi V; Rojas J; Paez E; Tapia S; Zolezzi P; Advis P
Med Pediatr Oncol; 1999 Aug; 33(2):88-94. PubMed ID: 10398182
[TBL] [Abstract][Full Text] [Related]
16. The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia.
Patte C; Auperin A; Michon J; Behrendt H; Leverger G; Frappaz D; Lutz P; Coze C; Perel Y; Raphaël M; Terrier-Lacombe MJ;
Blood; 2001 Jun; 97(11):3370-9. PubMed ID: 11369626
[TBL] [Abstract][Full Text] [Related]
17. [Molecular genetic detection of minimal residual disease (MRD) in children with acute lymphoblastic leukemia].
Koehler R; Bartram CR
Klin Padiatr; 2013 May; 225 Suppl 1():S40-4. PubMed ID: 23700054
[TBL] [Abstract][Full Text] [Related]
18. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica.
Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi A; Miniero R; Di Tullio MT; Lo Nigro L; Pession A; Rondelli R; Messina C; Santoro N; Mori PG; De Rossi G; Tamaro P; Silvestri D; Biondi A; Basso G; Masera G
Haematologica; 1998 Sep; 83(9):791-9. PubMed ID: 9825576
[TBL] [Abstract][Full Text] [Related]
19. Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studies.
Biondi A; Rizzari C; Valsecchi MG; De Lorenzo P; Aricò M; Basso G; Locatelli F; Lo Nigro L; De Rossi G; Masera G
Haematologica; 2006 Apr; 91(4):534-7. PubMed ID: 16537119
[TBL] [Abstract][Full Text] [Related]
20. Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331.
Maloney KW; Devidas M; Wang C; Mattano LA; Friedmann AM; Buckley P; Borowitz MJ; Carroll AJ; Gastier-Foster JM; Heerema NA; Kadan-Lottick N; Loh ML; Matloub YH; Marshall DT; Stork LC; Raetz EA; Wood B; Hunger SP; Carroll WL; Winick NJ
J Clin Oncol; 2020 Feb; 38(6):602-612. PubMed ID: 31825704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
